CO53 Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study
The fixed -ratio combination of insulin glargine (iGlar) plus lixisenatide (iGlarLixi) has proven efficacious in clinical trials; however, there is limited evidence of its benefits in diverse, real-world patients with type 2 Diabetes Mellitus (T2DM) who present in routine clinical practice. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: A. Chauhan, M. Samnaliev, J. Ken-Opurum, S. Sai Srinivas, A.M. Mehta, T. Dex, S. Charland, A. Revel, R. Preblick Source Type: research
Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study
ConclusionsThis real-world study demonstrated the effectiveness of iGlarLixi for improving glycemic control and decreasing body weight in people with T2D who need to advance therapy from OADs or insulin. (Source: Diabetes Therapy)
Source: Diabetes Therapy - May 21, 2023 Category: Endocrinology Source Type: research
Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials
Rev Diabet Stud. 2023 Mar 31;19(1):14-27. doi: 10.1900/RDS.2023.19.14.ABSTRACTIn type 2 diabetes, therapeutic failure to the oral anti diabetics is frequent, the use of schemes with basal insulin or with multiple doses of insulin (basal insulin and short-acting insulins) are a widely accepted way to intensify therapy. The use of GLP-1 receptor agonists is another intensification strategy. The fixedratio combinations with molecules such as insulin degludec + liraglutide, and insulin glargine + lixisenatide have proven useful in intensifying treatment of individuals with type 2 diabetes. The purpose of this review was to eva...
Source: Review of Diabetic Studies - May 15, 2023 Category: Endocrinology Authors: Hernando Vargas-Uricoechea Juan Pablo Frias Hernando David Vargas-Sierra Source Type: research
Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials
Rev Diabet Stud. 2023 Mar 31;19(1):14-27. doi: 10.1900/RDS.2023.19.14.ABSTRACTIn type 2 diabetes, therapeutic failure to the oral anti diabetics is frequent, the use of schemes with basal insulin or with multiple doses of insulin (basal insulin and short-acting insulins) are a widely accepted way to intensify therapy. The use of GLP-1 receptor agonists is another intensification strategy. The fixedratio combinations with molecules such as insulin degludec + liraglutide, and insulin glargine + lixisenatide have proven useful in intensifying treatment of individuals with type 2 diabetes. The purpose of this review was to eva...
Source: Review of Diabetic Studies - May 15, 2023 Category: Endocrinology Authors: Hernando Vargas-Uricoechea Juan Pablo Frias Hernando David Vargas-Sierra Source Type: research
